Stockscreener 앱 받기
100.30
2.36%
-2.42
Abbott Laboratories 주식(ABT)의 최신 뉴스
Jury awards total of $70 million in damages in case against Abbott over infant formula - The Guam Daily Post
Jury orders Abbott to pay US$70mil in preterm infant formula trial - Free Malaysia Today
Abbott Laboratories to pay $70M in damages in infant formula lawsuit - Chicago Sun-Times
Is Abbott Laboratories (ABT) Appealing After Recent Share Price Pullback? - Yahoo Finance
Chicago jury awards millions to families after babies fall ill after consuming Abbott Laboratories formula - ABC7 Chicago
Jury orders Abbott to pay $70 million in preterm infant formula trial, company says - Reuters
Cook County jury awards total of $70 million in damages in cases against Abbott over infant formula - Chicago Tribune
Abbott Jury Awards at Least $53 Million in Infant-Formula Trial - Bloomberg.com
Abbott (ABT) Ordered to Pay $17M in Baby Formula Case - GuruFocus
Abbott Ordered to Pay $53 Million in NEC Baby Formula Trial as Punitive Damages Loom - Consumer Notice
Abbott Laboratories stock (US0028241000): Is diagnostics strength enough to counter nutrition pressu - AD HOC NEWS
Abbott Laboratories Stock (ABT) Moved Down by 3.04% on Apr 10: A Full Analysis - TradingKey
-3.05% for Abbott Laboratories stock as persistent selling outweighs support - Traders Union
Abbott Laboratories stock hits 52-week low at $100.85 By Investing.com - Investing.com South Africa
Abbott Laboratories stock hits 52-week low at $100.85 - Investing.com
Abbott Laboratories price faces negative outlookForecast today10-04-2026 - Economies.com
Abbott survey finds ‘information overload, confusion and cost’ affecting health choices in US - Fierce Pharma
Dividend Roundup: AGNC Investments, Abbott Labs, AbbVie, and more (AGNC:NASDAQ) - Seeking Alpha
Abbott Laboratories: Solid Q1 Setup and Resilient MedTech/Diagnostics Support Path to 2026 Targets Amid Manageable Geopolitical Headwinds - TipRanks
How Abbott Baby Formula Verdict and Rising Litigation Risk May Reshape Abbott Laboratories' (ABT) Investment Profile - simplywall.st
Abbott Laboratories (ABT) Ordered to Pay $53M Over Infant Formul - GuruFocus
Chicago jury orders Abbott to pay $53M in preterm infant formula trial - Seeking Alpha
Abbott jury awards at least US$53 mil in infant-formula trial - The Edge Singapore
Jury orders Abbott to pay US$53 mil in pre-term infant formula trial, says Chicago Tribune - The Edge Malaysia
Abbott jury awards at least $53 million in infant-formula trial - MSN
Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says - Yahoo! Finance Canada
Abbott Laboratories must pay at least $53 million in cases over infant formula, jury decides - The Daily Gazette
Could Buying This Dividend Pharma Stock Today Set You Up for Life? - The Motley Fool
Abbott Hit With $53M Verdict Over Baby Formula Harms - Law360
How The Abbott Laboratories (ABT) Investment Story Is Shifting With New Targets And Trial Updates - Yahoo Finance
Goldman Sachs Lowers Price Target for Abbott Laboratories (ABT) Today | ABT Stock News - GuruFocus
Abbott India Ltd stock: Why it's drawing global investor attention now - AD HOC NEWS
Abbott Laboratories (ABT) likely to benefit from nutrition segment recovery - MSN
Abbott (ABT) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Most Americans think chronic disease is preventable — few know what to do - Stock Titan
DNA Sequencing Market Leading Players AnalysisAbbott - openPR.com
Rep. Richard McCormick Buys Abbott Laboratories Stock - National Today
Jury Deliberating in Cook County Case Over Abbott Laboratories' Formula for Premature Babies - National Today
Jury Deliberates in Case Over Abbott Formula for Preemies - National Today
Assessing Abbott Laboratories (ABT) Valuation After Precision Oncology Integration With Flatiron Health - simplywall.st
Jury deliberating in Cook County case over Abbott Laboratories’ formula for premature babies - Chicago Tribune
Abbott (ABT) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Yahoo Finance
Abbott Urges Ill. Jury To Reject Claims Formula Led To NEC - Law360
Abbott Laboratories stock rises Wednesday, still underperforms market - MarketWatch
Exocrine Pancreatic Insufficiency Market: Expanding Revenue Landscape to 2034 – DelveInsight | First Wave BioPharma, Abbott Products, AAIPharma, Solvay Pharmaceuticals, Abbott, Forest Laboratories - Barchart
A dividend king on sale: Is Abbott Labs a healthcare bargain? - MSN
Richard Dean Dr McCormick trades in various stocks, including Microsoft and Abbott Laboratories - Investing.com India
Barclays Adjusts Price Target on Abbott Laboratories to $144 From $142, Maintains Overweight Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $121 From $140, Maintains Buy Rating - marketscreener.com
Bacterial Vaginosis Market Is Going to Boom | Abbott Laboratories • Quidel Corporation • Hologic - openPR.com
Citi Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $136 - 富途牛牛
Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy? - qz.com
Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - Yahoo Finance
Abbott Laboratories (ABT) latest stock news and headlines - Yahoo Finance Australia
Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings - Insider Monkey
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain? - MarketBeat
Digital Health Monitoring Devices Market Report 2026-2030: Featuring Profiles of Philips Healthcare, Medtronic, GE Healthcare, Abbott Labs, Omron Healthcare and More - Yahoo Finance
Abbott Laboratories stock: Trading at a discount amid steady growth potential - AD HOC NEWS
Diabetes device recall surge reveals a worrying information gap - modernhealthcare.com
Evercore ISI Lowers Price Target for Abbott Laboratories (ABT) t - GuruFocus
Medical Foods Market Is Going to Boom |• Abbott • Danone - openPR.com
Evercore Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $134 - 富途牛牛
0.00%
0.80%
자본화:
|
볼륨(24시간):